By detecting the subtle brain changes and damage to nerve cells years before memory or language issues surface, the blood test allows patients to seek treatment during the window when therapies are most effective.
A breakthrough blood test capable of detecting Alzheimer’s disease up to a decade before physical symptoms appear is transforming how public health leaders approach the neurodegenerative condition.
With more than 7 million Americans currently living with Alzheimer’s — a figure projected by the Alzheimer’s Association to nearly double by 2050 — the test offers an unprecedented window for early intervention. Rather than waiting for irreversible memory loss and cognitive decline to set in, doctors can now identify signs of the disease while patients are still clinically healthy.
Former Centers for Disease Control and Prevention (CDC) director Dr. Robert Redfield highlighted the diagnostic breakthrough as a turning point in modern medicine on EWTN News Nightly.
“The FDA has approved, actually, a blood test that can give you high suspicion that you have Alzheimer’s,” the Catholic physician told anchor Veronica Dudo.
Catching the Disease in Its Preclinical Stages
Traditionally, Alzheimer’s has been diagnosed only after a patient exhibits clinical dementia. However, medical consensus now recognizes
